A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
University of Massachusetts, Amherst
Pharmacyclics LLC.
SWOG Cancer Research Network
University of Chicago
M.D. Anderson Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
BeOne Medicines
BeOne Medicines
Espad Pharmed
Hope Biosciences Research Foundation
Fred Hutchinson Cancer Center
Gilead Sciences
Incyte Corporation
Acerta Pharma BV
Novartis
H. Lee Moffitt Cancer Center and Research Institute
University of Washington
University of Washington
Thomas Jefferson University
Acerta Pharma BV
Novartis
National Cancer Institute (NCI)
City of Hope Medical Center
Universität des Saarlandes
UNC Lineberger Comprehensive Cancer Center
Insel Gruppe AG, University Hospital Bern
University of Washington
Georgetown University
Celgene
Masonic Cancer Center, University of Minnesota
University of Maryland, Baltimore
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Eisai Inc.
Masonic Cancer Center, University of Minnesota
Janssen Research & Development, LLC
PrECOG, LLC.
Mayo Clinic
Celgene
Ohio State University Comprehensive Cancer Center
CarboFix Orthopedics Ltd.
City of Hope Medical Center
AIDS Malignancy Consortium
Indivior Inc.
Incyte Corporation